Synthesis of Novel Artemisinin, Ciprofloxacin, and Norfloxacin Hybrids with Potent Antiplasmodial Activity
-
Published:2024-02-01
Issue:2
Volume:13
Page:142
-
ISSN:2079-6382
-
Container-title:Antibiotics
-
language:en
-
Short-container-title:Antibiotics
Author:
Vamvoukaki Georgia1, Antoniou Antonia I.1ORCID, Baltas Michel2ORCID, Mouray Elisabeth3, Charneau Sebastien34ORCID, Grellier Philippe3, Athanassopoulos Constantinos M.1ORCID
Affiliation:
1. Synthetic Organic Chemistry Laboratory, Department of Chemistry, University of Patras, GR-26504 Patras, Greece 2. CNRS, LCC (Laboratoire de Chimie, de Coordination), Université de Toulouse, UPS, INPT, 205 Route de Narbonne, BP 44099, CEDEX 4, F-31077 Toulouse, France 3. MCAM, UMR 7245, Muséum National d’Histoire Naturelle, CNRS, CP52, 63 rue Buffon, F-75005 Paris, France 4. Laboratory of Biochemistry and Protein Chemistry, Department of Cell Biology, Institute of Biology, University of Brasilia, Brasilia 70910-900, Brazil
Abstract
The synthesis and antiplasmodial evaluation of new hybrids combining the pharmacophore structures of artemisinin, ciprofloxacin or norfloxacin, and 7-chloroquinoline are reported in this study. The first step for all of the syntheses is the obtainment of key piperazine esters intermediates bearing the drugs ciprofloxacin and norfloxacin. Using these platforms, 18 final compounds were synthesized through a multistep procedure with overall yields ranging between 8 and 20%. All compounds were screened for their antiplasmodial activity against the chloroquine-resistant Plasmodium falciparum FcB1 strain. Compounds 20, 21, 22, and 28, bearing an artesunate fragment with ciprofloxacin, exhibited IC50 values in the range of 3.5–5.4 nM and excellent selectivity indices. Among the compounds bearing the artesunate moiety on the norfloxacin, two of them, 23 and 24, afforded IC50 values of 1.5 nM and 1.9 nM, respectively. They also showed excellent selectivity indices. The most potent compounds were also evaluated against the CQ-resistant Dd2 strain of Plasmodium falciparum, demonstrating that those compounds incorporating the artesunate fragment were the most potent. Finally, the combination of artesunate with either ciprofloxacin or norfloxacin moieties in a single molecular entity proved to substantially enhance the activity and selectivity when compared to the administration of the unconjugated counterparts artesunate/ciprofloxacin and artesunate/norfloxacin.
Funder
CNPq, the CAPES/COFECUB program University of Patras
Subject
Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Pharmacology, Toxicology and Pharmaceutics,Biochemistry,Microbiology
Reference39 articles.
1. Compans, R.W., Cooper, M.D., Honjo, T., Koprowski, H., Melchers, F., Oldstone, M.B.A., Olsnes, S., Potter, M., Vogt, P.K., and Wagner, H. (2005). Quinolines and Artemisinin: Chemistry, Biology and History BT-Malaria: Drugs, Disease and Post-Genomic Biology, Springer. 2. Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on?;Shalini;Expert Opin. Drug Discov.,2021 3. Prasad Raiguru, B., Panda, J., Mohapatra, S., and Nayak, S. (2023). Recent developments in the synthesis of hybrid antimalarial drug discovery. Bioorg. Chem., 139. 4. Medicinal chemistry updates on quinoline- and endoperoxide-based hybrids with potent antimalarial activity;Uddin;RSC Med. Chem.,2021 5. Quinoline hybrids and their antiplasmodial and antimalarial activities;Hu;Eur. J. Med. Chem.,2017
|
|